Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.
Two pharmaceutical companies are eager to advance a different approach to treating lung cancer.
A method of delivering chemotherapy drugs into a deadly type of brain tumor extended the lives of patients in early clinical trials.